A 22 month prospective assessment of neutralizing and IgG antibody levels against SARS-CoV-2 variants following homologous and heterologous BNT162b2 boosting.

Publication date: Jul 01, 2025

Open Access PDF

Concepts Keywords
Bnt162b2 Adult
Malaysians Aged
Pandemic Antibodies, Neutralizing
Vaccination Antibodies, Neutralizing
Antibodies, Viral
Antibodies, Viral
BNT162 Vaccine
BNT162 Vaccine
BNT162b2
CoronaVac
COVID-19
COVID-19 Vaccines
COVID-19 Vaccines
Female
Humans
Immunization, Secondary
Immunoglobulin G
Immunoglobulin G
Malaysia
Male
Middle Aged
Neutralizing antibodies
Prospective Studies
SARS-CoV-2
Variants of concern
Young Adult

Semantics

Type Source Name
disease MESH COVID-19
drug DRUGBANK Ilex paraguariensis leaf
drug DRUGBANK Coenzyme M
disease IDO host
disease MESH infection
disease IDO protein
disease MESH breakthrough infections
disease MESH Emergency
drug DRUGBANK Aluminum hydroxide
disease IDO history
disease IDO blood
drug DRUGBANK Amino acids
disease IDO infectivity
disease MESH Influenza
disease IDO country
disease IDO assay

Original Article

(Visited 6 times, 1 visits today)